When most of us encounter bacteria, we reach for a sanitizer. Researchers at the Cork Cancer Research Centre in Cork, Ireland, have a much different reaction. They view these single-cell microorganisms as literal torchbearers in advancing new therapies for infectious diseases especially as it relates to cancer.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lung cancer case study, Dr. Rimm uses this instrumentation to evaluate tumor infiltrating lymphocytes.
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a breast cancer case study, Dr. Rimm uses this instrumentation in her immune-oncology research.
Cancer researchers now can visualize more of a tumor than ever before using PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions. In a melanoma case study, Dr. Tumeh uses this instrumentation to develop biomarkers in his cancer immunology research.
A new generation of high-content imaging systems such as the PerkinElmer Operetta CLS High Content Imaging System and Harmony High Content Imaging and Analysis Software are helping scientists to blaze new trails in cancer drug therapy.
Researchers offer evidence of the importance of epithelial-to-mesenchymal transition (EMT) in the progression of chronic kidney disease.
PerkinElmer's Phenoptics™ quantitative pathology research system helped researchers reveal a predictive biomarker for Merkel cell carcinoma.
Using TIBCO Spotfire® visualization tools, PerkinElmer demonstrates this analytical versatile software in the study of infectious diseases.
PerkinElmer-GIS Centre for Precision Oncology leverages genome expertise and leading edge imaging instrumentation to develop new cancer therapies.
In a medical first, UNC researchers engineer and record skin cells becoming cancer killers using PerkinElmer’s IVIS system.
Monash Institute of Pharmaceutical Sciences is working to develop an inhaled oxytocin treatment for PPH, excessive bleeding after childbirth that kills an estimated 140,000 women a year.
Researchers at the University of Oklahoma have discovered potent polyphenols in brown seaweed that target and prevent the spread of pancreatic cancer cells. Their research is a potential blueprint for fighting the most lethal form of cancer, saving thousands of lives each year.
Using a suite of PerkinElmer's analytical imaging instruments, Dementias Platform United Kingdom (DPUK) is taking a whole-body approach to early detection, better treatment, and prevention of neurodegenerative conditions including Parkinson’s Disease, Motor Neurone Diseases, Multiple Sclerosis, Huntington’s Disease, Creutzfeldt–Jakob Disease, and Alzheimer’s Disease.
Scientists morph stem cells into mini-brains to prove that the Zika virus causes massive brain cell death in fetuses.
Groundbreaking research using PerkinElmer's Vectra multispectral imaging platform may lead to new immunotherapy treatments for cancer.
Using high content cellular imaging to engineer new drug therapies to combat human diseases.
High-tech imaging systems help identify new drugs to fight multiple sclerosis.
Visualizing tumors with PerkinElmer’s Solaris™ imaging system.
New multispectral cell imaging system aims to revolutionize tumor analysis
Shining a new light on cancer: A novel bioluminescent probe will help improve cancer treatments
Novel test identifies lung cancer patients most likely to benefit from immune therapies
Casting a new light on breast cancer
Turning off gene signaling to cure pancreatic cancer
Our quest to improve life goes back to our earliest innovators, but the challenges we face today have never been greater.
In Mice and Men: Gene Therapy Prevents Muscular Dystrophy
Yale University research shows reversal of memory loss from Alzheimer's disease.
Chinese researchers develop a "magic bullet" against Parkinson's disease with the help of PerkinElmer.
PerkinElmer’s Solaris™ open-air fluorescence imaging system displays tumors in real time on large monitors under normal lighting conditions.
PerkinElmer’s Vectra platform is helping to advance research into immuno-oncologic treatments.
Researchers are searching for ways to restore neural function after traumatic brain injuries. Research using human neural stem cells (hNSCs) is showing promise.
The European ScreeningPort (ESP) enables academic researchers with promising data on the causes of disease to get physiologically relevant results and help support translating them into potential new therapeutics.
By studying changes in the shape of cells and organelles in response to cancer drugs, researchers hope to pave the way for more effective breast cancer treatments.
Small research facilities combine high-value expertise with high-quality instrumentation to support cell and tissue-based research at Edinburgh University and beyond.
With PerkinElmer’s solution researchers can now detect, measure, visualize, and compare multiple immune-cell phenotypes simultaneously in a tissue section.
Using a state-of-the-art antibody technology platform, AIMM develops desperately needed therapeutics to improve treatment of inflammatory, autoimmune and infectious diseases.